



Improving patient outcomes in cervical myelopathy

The Lord Carter of Coles

Your excellency, Lords, members House of Commons, ladies and gentlemen it gives me enormous pleasure to welcome you tonight to the House of Lords. I'm sorry the weather isn't a little bit better but at least we've got the view. Those of you who have not been before, I hope you enjoy the setting, and those who have, and all of us, I hope you enjoy the occasion.

I think it's fitting, and very impressive, to welcome guests from all over the world, people have come from the west coast of the States, from Singapore, from Canada, and from all over Europe. I think it's also notable that the people that have attended are leaders in their world, in the medical world, in the scientific world. But also I think what's really, really important is that we have people here who actually suffer from the condition, suffer from Myelopathy and can explain to us what it's like to have this really debilitating condition and to prove how vital it is that we all act together now to do something about it.

I think it's estimated that 5% of the population over 40 are at risk of Myelopathy, it's a bit hard to know the precise figures because actually in a sense we haven't addressed the issue of measuring it, but it's the most common cause of spinal cord injury. What I hadn't realised is it causes a wide range of disability and can lead to things like incontinence, double incontinence and a wheelchair existence which after all is extremely limiting. So, it's really critical that we raise awareness. I think part of our mission is to raise awareness among clinicians especially non-specialists and other healthcare professionals, to get that early diagnosis and to do that we need the help of all of you in this room, we need legislators, we need educators, we need opinion formers and of course, we need the public at large to be aware of what we're doing. It's critical that we get an early diagnosis, it's not something to be glossed over.

It's critical if we're to prevent the worst aspects of this crippling and progressive illness really [that] we get this on the agenda, it becomes really important.

Earlier today Myelopathy.org hosted a symposium of professionals and that highlighted the latest developments in research and treatment. Now the organisation, and that's what it's there for, plans to do much more in this area particularly to develop treatment and cures but to answer some of the basic questions because actually how can you do this if you haven't answered those. I think there are four basic questions the first is how common is it? The second is, is it age-related? What are the dynamics of it? Other questions [include], are certain groups more at risk than others? and how does functionality relate to spinal cord damage?

So again thank you very much for coming I think over really to the to the experts now and the first of those is Professor Fehlings who has come from Toronto to be with us tonight. I think many of you have seen in the notes about his distinguished career, [he's a] highly distinguished neurosurgeon and [combines] clinical practice and research in Toronto. His specialism is spinal injury and the repair and regeneration arising from that and of course he's had much recognition typically things like the Nobel Institute among others and we're really honoured to have him here tonight.

Prof Michael Fehlings

Well Lord and Lady Carter of Coles thank you so much for hosting this wonderful event and for your support of Dr Kotter and his amazing team which has had the vision to establish Myelopathy.org. I also wanted to recognise Cambridge University Professor Hutchison and the team that has really supported Mark and provided the infrastructure to enable the creation of this event and of course, there are

many other sponsors that are recognised here.

I also wanted to acknowledge and recognise the individuals in the room who have cervical myelopathy, you are really the inspiration to us all and you have much to teach us and we're trying very hard to help [you]. So, I was asked earlier today what got me interested in cervical myelopathy so let's just play a game for a moment I want you to look to your left and now look to your right one in three individuals in the United Kingdom will develop a serious neurological disorder. We're very well aware of some of these serious neurological disorders, Stroke, Alzheimer's disease, traumatic spinal cord injury, which has been my main area of interest for many years. But degenerative cervical myelopathy is arguably one of the most common neurological conditions. Perhaps as many as 5% of individuals in our society will have a cervical myelopathy and this can cause significant loss of motor function, movement, control of the hands, loss of a lower limb function, loss of bowel and bladder a function, loss of Independence, and significant neuropathic pain. I bet prior to this event and prior to the creation of Myelopathy.org that many of the non-medical and non-healthcare related people here probably had never heard of this condition and we need to change this. We need to raise the awareness of this condition. This is a treatable condition if diagnosed at an early stage. There's effective surgical treatment that can arrest the course of this condition that can result in some improvement. It's very important that individuals in society be aware of this condition to know what's going on just as we've had educational programs to raise awareness for of the symptoms and signs of stroke. It's also very important for us to reach out to the GPs, the GPs are the anchor of the healthcare system the GPs really are the ones that will see individuals at the first stage and they need to understand what the issues are and to think of this diagnosis and to achieve this diagnosis.

We need the help of all of you also to raise the awareness and the importance of research. While we have the ability to diagnose cervical myelopathy and while we have treatments

that are effective unfortunately the treatments only get us so far and the reality is that many patients despite our best efforts continue to suffer from neuropathic pain and the impairments of spinal cord dysfunction. It's my hope that this organisation and the influential people here in this room will raise the banner and will enable research efforts to occur - to enable clinicians to further help patients. So, I just want to acknowledge and thank Mark Kotter and his Cambridge team for having the vision to establish Myelopathy.org. I think it's a wonderful opportunity to engage the community and to help people with this disabling condition thank you.

Lord Carter of Coles

Our next our next speaker and somebody to whom we all owe, professionally and personally, a great deal is Mark Kotter. Mark is [a] founder of Myelopathy.org and he's now a trustee of that organisation such is his commitment to taking this forward. [As] an academic neurosurgeon at Addenbrookes in Cambridge he's developed clinical and research interests in spinal injury and Myelopathy. It's good to know that actually some of the public funding is being deployed in this and he's currently funded by the National Institute for Health Research and I should say we're all very grateful to them for the support of Mark in this program. I think what's distinguished Mark's approach to this is the involvement of patients in Myelopathy.org this isn't some sort of scientific thing that isn't grounded. [The] creation of this support group owes very much to Mark's vision of how the patient community should be built and how they can contribute to the future development. Mark can I hand over to you? Thank you.

Dr Mark Kotter

Thank you, Patrick, and thank you Julia, your excellency and all the distinguished guests. I wanted to tell you a little bit about how my interest and this organization started up. I was a mid-tier spine surgeon neurosurgical trainee and I was left to do my first high cervical spine surgery on my own. [It was on] an 80-year-old lady with cervical myelopathy and it was a rather simple procedure at this point. I took her through the steps of the operation, I tried

to tell her about the risks and the benefits of the operation and she eyed me up and what I learned very quickly is that she was [a] highly experienced nurse so in a second she knew who was in front of her. Nevertheless, I was able to instil some confidence in her and or perhaps she installed some confidence in me, [and] she accepted that she had to do this. The surgery went well, [and] she went home the next day. She had the expected improvements, which are very mild after such surgeries but what I didn't realize is when she allowed me to operate on her we [apparently] entered into a contract and the contract was in return for being my patient and I had to give her information. So, she would send me letters every 3-4 months [each] between five and ten pages long and [they would include] minute details of her life and her struggles. They were full of questions such as, What can I do about my numb and clumsy hands? When can I expect to be walking without [a] stick? How can I change the urgency that takes me out of bed in the night in order to reach the toilet? And what I did [was] I went to the scientific literature and I tried to look up all the questions and I tried to write answers [but] I couldn't find any answers in the literature.

This is really a good example of what the NIHR is trying to address precisely that lack of patient input in research [which] has led to the concept of research wastage. Chalmers et al published in a very eminent medical journal that [a] huge amount of research money [is] spent without taking into account the patient perspective. Since I met this lady we have [come] a long way, a lot of really good research has started to emerge often led by Professor Fehlings out of Canada who did some of [the] largest global assessments of how patients do after the surgery and this has given us some information [about] how we can address this disease and what the gaps are.

So really Myelopathy.org [was] founded to do three things, the first thing, and we've heard it before already, is to give myelopathy sufferers a voice. We've heard that it is often progressive, but it can be stopped with surgery, but the problem is if you don't get surgery at the right time then you lose function and what you've lost

is irreversibly lost in most cases. So, we need to educate health professionals, we need to educate the general public about the condition, about the urgency that comes with it. The second important aspect of Myelopathy.org is that we need to ask questions and so the single biggest factor [is] these delays [in diagnosis and treatment] so the question is, how can we change this? What do we need to put in place in order to recognise the disease earlier? What are the diagnostic algorithms that we need to put together to not miss out at the early stages? And what are the changes that we can [make] to patient pathways so that they are not lost in the system. When we looked at our particular healthcare system in Cambridge, we found that patients were moving through the system like Brownian [motion] so very erratic until they actually at some point met a specialist with an interest in this. So [the final] big question is about the basic science and the research. In 2017 we did a systematic review, we tried to gather all information that had ever been published on [the] basic science in cervical myelopathy and we found a total of 50 different articles, [this] compares to tens of thousands of articles in the traumatic spinal cord injury literature. If you think about how frequent the condition is there is a huge mismatch in terms of what we do in science and what is required for society.

Patrick and Michael you've also alluded to the question of who is at risk, because many of us will get degenerative changes in the neck, we just seem to be living a bit too long and our heads seem to be a bit too heavy for our necks and that causes wear out of the spine. At the age of 80, 80% of us will have cord compression thankfully not all of us will have myelopathy [so] why do certain individuals get the condition and others not? And of course, if we have this information, we can make better decisions about surgery, who needs an operation? who needs treatment at an early stage?

The last important aspect of myelopathy.org is we're here to affect change so we want to connect individuals with the condition so that they can share their experiences and they can

come together and help others understand what needs to be done in order to address their needs. We need to raise awareness and we're very grateful for this evening because this is, of course, a fantastic opportunity to get the message out.

Although we are really at the moment an organisation of volunteers we have teamed up with the AO spine which is the largest network of surgeons worldwide and together we were able to do two things, one of them is a core outcome initiative, the idea of this is to standardise what we measure in myelopathy patients and how we can standardise clinical trials so that they become comparable. One of the things that we found when we looked at the literature [was that] some studies look at this aspect [and] other studies look in another aspect and you can't integrate together and that limits your learning from the condition. And the second big important thing is the question about what's important for you what's important for individuals that have myelopathy and here we have launched, again together with the AO spine and helped by the NIHR, our James Lind Alliance a research priority setting exercise and this will involve multiple rounds of surveys and then actually physical interactions of multi-stakeholders.

Lord Carter of Coles

Our next speaker Dr Iwaki is founder and president of MediciNova a California-based bio-pharmaceutical company. Dr Iwaki was educated in Japan but interestingly spent a number of years in an academic post in the United States which obviously gave him the grounding to establish the MediciNova. His company works closely with Dr Kotter on the regenerative research program.

Dr Iwaki

Thank you very much Lord Carter. Ladies and gentlemen and colleagues, friends. It is my distinct honour to present [at] such an exciting event, the launch of the world's first charitable organisation [for cervical myelopathy], Myelopathy.org. It was more than four years ago [that] I received the email from Dr Mark Kotter asking about the potential collaboration

to treat degenerative cervical neuropathy with our potential miracle drug because our compound was shown to protect [against damage] caused by neural degeneration. He concluded his email with the phrase "I trust that my proposal finds your interest and look forward to hearing from you". Yes, we had a deep interest as our company's mission is to develop drugs for patients [where no] effective treatment [currently exists]. However, it was not smooth path by way of an analogy the difference is more than that of chopsticks and knife and fork. However, that this project by Dr Kotter and Ben Davies from the University Cambridge and Dr Matsuda Chief Medical Officer from MediciNova [overcame these trials is] noted from a kick-off meeting [for the clinical trial] this morning. I now recognise how powerful the [collaboration between the teams] at Cambridge and MediciNova is because their and our mission [is] "For The Patient". This is a really wonderful international collaboration [between] Japan, the United States and the United Kingdom. I'm sure that more collaborative work will follow. Lastly, I would like to promise that we at MediciNova will support activities of this charitable organisation, Myelopathy.org a history-making endeavour, for a long time. Thank you very much.

Lord Carter of Coles

I'd like to ask his Excellency Mr Tsuruoka the ambassador for Japan in this country to come forward. We're very lucky he's come tonight. Ambassador since 2016 with a distinguished career in the Japanese Foreign Service. If you've got a moment do have a look at his bio because it's extremely interesting, vast experience particularly in the area of international trade. I don't believe any one country can do these things, we need to collaborate, we need to find out what we're good at and we need to pull these things so we can get these amazing developments to the market quickly. Your excellency.

Mr Tsuruoka

Thank you very much for a kind introduction Lord Carter. My Lords, members of parliament, distinguished guests. To tell you the truth I really don't know why I'm here. You, of course, have guessed right I have no expertise [in]

medicine, pharmaceutical or any health-related issues but that is not really important as long as the framework for international collaboration is being built up. Japan has been on the forefront of creating the healthy world, one of the contributions I myself made, and I am a professional foreign service officer, [was to make] medical issues part of diplomacy. I was able to have my foreign minister, about ten years ago, write to the medical [journal] The Lancet as foreign minister, for the first time, about expanding [and] strengthening global healthcare. That is in our blood as well as the blood of the British people. Your NHS, of course, is a very strong source of your pride. We also have a national healthcare system which we are very proud of although the government being a bit poorer than the British government now charges 30% of the medical fee when you have to resort to medical service in Japan. Still we are happy and fortunate because most people can afford that and there are exemptions to that. There are many challenges that the world has faced on a day to day basis and I really wasn't aware, as many of [the] previous speakers have pointed out, the problem of Myelopathy. I'm very happy that I've come because I've learned one more thing today which I believe is very important and it is going to affect the future of many people in many generations. Unless we do [something] now we may be too late, perhaps we are a bit late, but late is always better than never and I think the starting of this collaboration [between the] UK, US and Japan and of course many other countries joining in and expertise coming from different parts of the world is going to assure us with success of the research and efforts that we will be putting in. Because unless you have very strong personal commitment these collaborations never happen. I've just been convinced that Lord Carter and the founders of Myelopathy.org are people who are truly committed to addressing this very difficult issue. They are not just contributing to what may happen to their relatives, friends or people in the UK, this is going to be a global issue, it is already a global issue because life science by definition [has] no border. You have to do the work which will be beneficial to the rest of the world. That's why Japan has put this as

a very important diplomatic priority because we are convinced that no one country can do it alone and no one expert can do it alone. It needs lots of collaboration among different countries, expertise of a diverse nature but also funding. I'm very happy that MediciNova, which is funded by a Japanese entrepreneur, has chosen to put [in] capital to promote this. By the way, this person is an entrepreneur who made his gigantic wealth in one generation. He's created lots of video games and Anime movies and so forth. He wants to be useful, he wants to invest in the future. I met him in Tokyo when I was there a couple of months ago and his dream is to be able to contribute to the future, to the generation that will follow us because we will continue to prosper for sure despite the B-word. I will just say one [more thing], the UK excels in the ability of promoting R&D, especially the high tech, the cutting-edge technologies and what Japan can do together with this expertise is to join forces to develop something that could be applicable and perhaps in the future become commercially available, that will be not limited to anyone it will be open and made available to all. This is what I believe diplomacy should focus on and therefore it is not something that we will leave to the medical experts to address. I fully agree that we need to be aware of this issue and I'm very happy that I've come because I'll be bringing back the message [and] relating it to my government that my government also need to be more or engaged in promoting this at the global arena. Thank you very much for your attention.

Lord Carter of Coles

I have to say your excellence that's the most elegant exposition of public diplomacy that I've heard. To sort of make it possibly more relevant in the sense to the wider world I think perhaps we can hear now from two people [who suffer from myelopathy]. Perhaps first, from Shirley Widdop who's a member of Myelopathy.org. She was diagnosed in 2012 but she's been a tremendous and key member of the Facebook support group as well as a very, very effective ambassador for myelopathy nationwide.

Shirley Widdop

Lords, ladies and gentlemen, Ambassador,

distinguished guests. My thanks to Lord and Lady Carter of Coles for their most gracious invitation to this most auspicious event. I am extremely proud and privileged to be here. What a wonderful way to celebrate Myelopathy.org's official launch.

I am a volunteer for Myelopathy.org and I help them spreading the word. I go to the conferences with our trade stand and I'm also an admin on Myelopathy Support on FB founded by Iwan Sadler who you'll hear from in a minute. I have been asked to speak from a patient's perspective about what myelopathy means to me. In a nutshell; it has proved to be a life of momentous change. When I acquired myelopathy in 2011, I was 44 years old, reasonably fit and healthy, fiercely independent and a lone parent to three boys aged 15, 13 and 7. Although I am a haematology nurse by profession, I was working part-time as a home help and studying for a degree in Psychology from the Open University. A morning stretch on waking, whilst sat on the loo of all places, changed my life forever as, unbeknown to me at the time, apart from the excruciating pain; an intervertebral disc had prolapsed. Initially, the GP thought I had carpal tunnel syndrome. A nerve conduction study soon ruled this out. I was subsequently referred to a neurologist whom I saw in October that year. But in the meantime, I rapidly progressed to full blown myelopathy - problems with manual dexterity, pain, fatigue, difficulty walking, climbing hills, climbing stairs, balancing and recurrent falls. I had an MRI scan of my head and neck in January 2012 and was diagnosed with classical Cervical Myelopathy in March - the disc had prolapsed at the C6/C7 level. I basically had no spinal cord left, I was surprised I was still walking. I was referred to Leeds General Infirmary and underwent a C6/C7 anterior cervical discectomy with fusion in September 2012. But, due to the length of time my spinal cord was compressed, I never regained full function, I am now permanently disabled as a result.

At the time of diagnosis, the only information I could find out about myelopathy was that it was a disease in dogs - particularly German

Shepherds. It was by pure coincidence that an online questionnaire about myelopathy I competed led to an invitation to the very first Patient Participation Day at the University of Cambridge in September 2016. I nearly didn't go, because I was in too much pain and too tired. But, I went. There I met Mark, Ben, Iwan plus other researchers and patients. I was invited to join the support group Iwan had set up in the meantime. The rest is history...

I now volunteer because it's simply not right that folk with myelopathy are too often dismissed as anxious, all in the head, or mis-diagnosed when it is vital we receive a prompt and timely diagnosis. Too often we are left waiting too long for MRI scanning, Nerve Conduction Studies and Electromyography Testing (EMGs). MRI scanning is a particular bugbear. We seem to be scanned in a piecemeal fashion - each part is looked at separately when the head, neck & spine should be scanned as a whole as a baseline to work from. Similarly, nationwide, there are insufficient numbers of upright dynamic scanners - scanners that are more accurate than the recumbent ones currently used. Too often are we slotted, as an afterthought, into the neurosurgical lists when we all know that "Time is Spine". Indeed, during a recent conversation at the BASS conference in Brighton, one neurosurgeon was of the opinion that folk with myelopathy should be treated as urgently as someone with a brain tumour.

Too often, myelopathy is considered a disease of older age, yet many of our FB members were under 55 years when diagnosed. A surprising number are in their 30s. How can it be that those with myelopathy are being failed in this way and suffer permanent disability and psychological trauma as a result? Indeed I'm sad to report one of our members recently tried to commit suicide due to the distress of being in so much pain, because he had reached the end of his tether. This is why the foundation of Myelopathy.org is so important.

Living with myelopathy is a roller coaster ride of emotions, whilst struggling to hang on for the ride. From utter terror at the thought of being

permanently paralysed, to total despair at being told you'll not regain full function, ever!

The lack of information out there about people like me, certainly in general practice and the hospitals is dire. The isolation of no one understanding what I was going through and subsequent dip into the pit of depression that was very difficult to escape. Thankfully, due to counselling and medication I made it out. If it were not for that, my sons and pets, I would not be here. I can't stress that enough, I am not joking when I say that. Too many of us are suffering as the support we need is either underfunded, oversubscribed or non-existent.

Similarly access to post op rehabilitation is a post-code lottery for many. Any additional help I received I had to advocate for it myself. But then there's hope and light at the end of the tunnel with the discovery of Myelopathy.org and Myelopathy Support. They have changed my life for the better, giving me the strength to hang on, not only for me and my family, but for all those people out there that will invariably go through what I went through. But, hopefully, not anymore; this time, they won't be alone. Myelopathy.org and Myelopathy Support will be there for them. Thank you.

Lord Carter of Coles

Well thank you Shirley. At the so-called higher levels of the NHS we talk about the patient voice [and] actually it's really very powerful to hear it, Shirley thank you very much it was really, really impressive. [Let's talk] about Iwan to whom we owe a great deal. He's living with myelopathy, he's disabled by the condition, diagnosed in his forties but then he did something about it, he founded the Facebook support group to help others. I think the thing that strikes you about [myelopathy] is the loneliness and the helplessness you can feel when faced with this I think what's impressive. This is something that the NHS can't do, it needs people, individuals, to go out and make a difference. How do we empower people to actually set up these things? and how do you get 2,000 people to come together and support each other? It's the wonder of technology but it takes people to do it, Iwan.

Iwan Sadler

I was really honoured to have been asked by Mark to say a few words here this evening, even under the strict instructions that I wouldn't mention Wales winning the triple crown and the grand slam but as a proud Welsh man I really couldn't let this opportunity slip especially on a prestigious stage like this.

Moving swiftly away from the Rugby. It's pretty surreal for me to be standing here today and to be part of this momentous occasion in launching the world's first charity for myelopathy. Looking back to 2014 I will never forget the feeling of isolation and the fear that I felt when I was first diagnosed with myelopathy. Those feelings were so strong within me, that it prompted me to start one of the very first Facebook community pages for the awareness of myelopathy. At the time I just wanted to make sure no one else would have to go through the emotional rollercoaster that I had, had to endure.

As humans, we have a deeply curious nature, and my mind was bombarded with questions that urgently needed answers. Unfortunately, however hard and long I searched I could only find a handful of unsatisfactory answers to my forever recurring questions.

The decision to set up my awareness page and to share my story with Myelopathy.org led me to meet Mark and Ben at the University of Cambridge in 2016. What immediately struck me was, here are two health professionals at the opposite end of the so-called spectrum of myelopathy and they radiated the same burning passion, determination and goals that I have as a person diagnosed with the condition. So, when they kindly asked me to join the team I jumped at the chance as I knew how beneficial this would be to the myelopathy community.

Now our online community grows daily as we reach to different corners of the world. This highlights the many features of a diagnosis: not only the physical challenges but also the mental challenges and the trip into the unknown. In fact, myelopathy is totally life-changing, not

only for you but also for the people around you. Emotionally and socially this condition will test you to the limits, and engulf you with variable symptoms that make daily living and forward planning an even bigger challenge.

Everything that I have mentioned highlights not only the importance of our awareness campaign but also the vital role our help and support group plays in making sure that people diagnosed with myelopathy don't have to feel isolated and fearful anymore. Just as importantly, we must make sure that our network reaches families and carers to give them a better understanding of this overlooked condition.

As they say: "from little acorns grow mighty oaks", and this is so true of Myelopathy.org. We have been fortunate to have volunteers who give us their valuable time and effort: this has been an essential factor of our growth and success. To all the admins, moderators and the rest of the team, I would like to thank you on behalf of the myelopathy community for your commitment and help that you have given. You have made a tremendous difference to so many people's lives already, and I hope you can remain with us as we grow and reach out to even more people so we can continue to be a part of their journey from diagnosis to treatment and recovery.

To see so many like-minded health professionals here this evening means so much to me and the rest of myelopathy community and sends out a clear message that, at last, we not only have a voice but most importantly we are being heard.

Thank you so much to everybody here this evening, and especially the support group members who have endured a painful journey as this condition is so relentless. May I thank

Lord and Lady Carter of Coles for their kind invitation, and also Michelle and the rest of the team for all their hard work to make this evening such a success.

Lord Carter of Coles

I have to say it's not often these days you can use the word uplifting but that really was. You get a chance to be present at something which can really change people's lives, how do we build on that? How do we actually take the lessons and share them with people not only in this country but globally? So, I think we're getting towards the end I would like to ask Mark Kotter to come up and so try and summarise where we've got to.

Dr Mark Kotter

Thank you very much once again for coming all together tonight. Thank you to Lady and Lord Carter for hosting Myelopathy.org here and for really giving us a wonderful and really unexpected opportunity to spread our word and connect with the larger public and the larger world of the NHS and healthcare system.

I would like to thank all the myelopathy support group members who made the journey here and those that weren't able to come today but wanted to be part of this wonderful event. I'd like to say thank you to Ellen Sarewitz, she has helped with the press releases, trying to find the right words to be communicated to a larger audience.

I think some of the most wonderful people I met in my career are Dr Michelle Starkey, Dr Gemma Wise and Dr Ben Davis without the three of them we wouldn't be here, we wouldn't have this organisation. They are hugely inspiring and wonderful people to work with and I'm it's my deep pleasure to be on this journey together with you.

www.myelopathy.org

✉ info@myelopathy.org

📷 [instagram.com/cervicalmyelopathy/](https://www.instagram.com/cervicalmyelopathy/)

📘 [facebook.com/myelopathy](https://www.facebook.com/myelopathy)

🐦 [@myelopathyorg](https://twitter.com/myelopathyorg)

*Myelopathy.org is a registered charity (charity no. 1178673).
Registered office Pioneer House, Vision Park, Histon, Cambridge, CB24 9NL*

